Crossject
Crossject Société Anonyme develops needle-free injection systems in France. The company develops ZENEO, needle-free, pre-filled, single-use auto-injector. Its product pipeline includes Midazolam for epileptic seizure; Naloxone for opioid overdose; Terbutaline for the treatment of severe asthma crisis; Epinephrine for anaphylactic shock; and Sumatriptan for the treatment of migraine and cluster he… Read more
Crossject (ALCJ) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2025: 2.893x
Based on the latest financial reports, Crossject (ALCJ) has a cash flow conversion efficiency ratio of 2.893x as of June 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-3.23 Million) by net assets (€-1.12 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Crossject - Cash Flow Conversion Efficiency Trend (2012–2024)
This chart illustrates how Crossject's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Crossject Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Crossject ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Meteoric Resources NL
OTCGREY:METOF
|
N/A |
|
SMARTOPTICS GRP AS NK-02
F:3YL
|
N/A |
|
Bombay Dyeing & Mfg Company Limited
NSE:BOMDYEING
|
-0.018x |
|
Lealea Enterprise Co Ltd
TW:1444
|
0.003x |
|
Fury Gold Mines Ltd
NYSE MKT:FURY
|
-0.068x |
|
Altius Renewable Royalties Corp
OTCQX:ATRWF
|
0.001x |
|
Laxmi Organic Industries Limited
NSE:LXCHEM
|
0.029x |
|
First Ottawa Bancshares Inc
PINK:FOTB
|
0.023x |
Annual Cash Flow Conversion Efficiency for Crossject (2012–2024)
The table below shows the annual cash flow conversion efficiency of Crossject from 2012 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €-2.67 Million | €-7.96 Million | 2.977x | +152.94% |
| 2023-12-31 | €-5.27 Million | €-6.20 Million | 1.177x | +162.23% |
| 2022-12-31 | €2.69 Million | €-5.08 Million | -1.891x | -270.39% |
| 2021-12-31 | €-5.48 Million | €-6.08 Million | 1.110x | -77.03% |
| 2020-12-31 | €-1.13 Million | €-5.46 Million | 4.833x | +364.36% |
| 2019-12-31 | €3.01 Million | €-5.51 Million | -1.828x | +62.27% |
| 2018-12-31 | €1.65 Million | €-8.02 Million | -4.845x | -492.85% |
| 2017-12-31 | €6.09 Million | €-4.97 Million | -0.817x | -16.62% |
| 2016-12-31 | €6.28 Million | €-4.40 Million | -0.701x | -28.56% |
| 2015-12-31 | €8.80 Million | €-4.80 Million | -0.545x | -149.64% |
| 2014-12-31 | €14.48 Million | €-3.16 Million | -0.218x | +78.53% |
| 2013-12-31 | €947.65K | €-964.00K | -1.017x | -440.48% |
| 2012-12-31 | €-1.90 Million | €-569.06K | 0.299x | -- |